The purpose of this study was to determine indication and the treatment outcome of Intravitreal Bevacizumab (IVB) Injection in retinal diseases in a community eye hospital in Nepal. This was a retrospective study of the patients with retinal diseases following Intravitreal Bevacizumab injections at Hetauda Community Eye Hospital from 2019 to 2022. We evaluated the data of 247 patients with 260 eyes treated with IVB to assess the effectiveness in the management of diabetic retinopathy(DR), neovascular age-related macular degeneration(nAMD), and branch retinal vein occlusion(BRVO), among other retinal conditions. The patients' average age was 64.4 years, with a male predominance of 56.1%. DR was the most frequent indication for IVB, followed by nAMD and BRVO. Central macular thickness(CMT) in BRVO and visual acuities in DR, nAMD, and BRVO considerably improved after IVB treatment. The findings emphasize the efficacy of IVB as a cost-effective treatment for retinal diseases at both visual and quality-of-life levels for resource-constrained settings. It is, therefore, an option that strongly needs to be considered as a form of treatment in such settings.